PRIVATE PATENTS AND PUBLIC HEALTH
private-patents-and-public-health
private-patents-and-public-health
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ange-big-pharma<br />
298 Ana Maria Henao-Restrepo et al,<br />
“Efficacy and effectiveness of an<br />
rVSV-vectored vaccine expressing<br />
Ebola surface glycoprotein: interim<br />
results from the Guinea ring<br />
vaccination cluster-randomised<br />
trial,” The Lancet 386, no. 9996: pgs.<br />
857-866, doi: 10.1016/S0140-<br />
6736(15)61117-5, 3 August 2015, http://<br />
lancet.com/pb/assets/raw/Lancet/<br />
pdfs/S0140673615611175.pdf<br />
299 Steven M. Jones et al., “Live<br />
attenuated recombinant vaccine<br />
protects nonhuman primates against<br />
Ebola and Marburg viruses,” Nature<br />
Medicine 11: pgs. 786-790,<br />
doi:10.1038/nm1258, 5 June 2005,<br />
http://www.nature.com/nm/journal/<br />
v11/n7/abs/nm1258.html<br />
300 One such example is the FDA priority<br />
review voucher. See: Alexander<br />
Gaffney, Michael Mezher,<br />
“Regulatory Explainer: Everything<br />
You Need to Know About FDA’s<br />
Priority Review Vouchers,” 2 July<br />
2015, http://www.raps.org/<br />
Regulatory-Focus/<br />
News/2015/07/02/21722/Regulatory-<br />
Explainer-Everything-You-Need-to-<br />
Know-About-FDA’s-Priority-Review-<br />
Vouchers/ and: PLOS Guest Blogger,<br />
“FDA Voucher for Leishmaniasis<br />
Treatment: Can Both Patients and<br />
Companies Win?” PLOS Blogs, 20<br />
January 2015, http://blogs.plos.org/<br />
speakingofmedicine/2015/01/20/fdavoucher-leishmaniasis-treatmentcan-patients-companies-win/<br />
301 Belen Pedrique, Nathalie Strub-<br />
Wourgaft, Claudette Some, Piero<br />
Olliaro, Patrice Trouiller, Nathan<br />
Ford, Bernard Pécoul, and Jean-Hervé<br />
Bradol, “The drug and vaccine<br />
landscape for neglected diseases<br />
(2000 — 11): a systematic assessment,”<br />
The Lancet Global Health 1, no.6:<br />
e371-e379, doi: 10.1016/S2214-<br />
109X(13)70078-0, December 2013<br />
302 Including: the Special Programme for<br />
Research and Training in Tropical<br />
Diseases (WHO-TDR), and three<br />
universities (University Hospital of<br />
Grenoble, France; Joseph Fourier<br />
University, France; University of<br />
Oxford, UK<br />
303 Belen Pedrique, Nathalie Strub-<br />
Wourgaft, Claudette Some, Piero<br />
Olliaro, Patrice Trouiller, Nathan<br />
Ford, Bernard Pécoul, and Jean-Hervé<br />
Bradol, “The drug and vaccine<br />
landscape for neglected diseases<br />
(2000 — 11): a systematic assessment,”<br />
The Lancet Global Health 1, no.6:<br />
e371-e379, doi: 10.1016/S2214-<br />
109X(13)70078-0, December 2013<br />
304 “Année du medicament,” Rev Prescrire<br />
2015 ; 35 (376) : 132-136, English<br />
translation available online here:<br />
http://english.prescrire.org/en/109B5<br />
61E03CAD2313B7046521B310752/<br />
Download.aspx<br />
305 “Année du médicament” Rev Prescrire<br />
2015; 35 (376): 132-136, English<br />
translation available online here:<br />
http://english.prescrire.org/en/109B5<br />
61E03CAD2313B7046521B310752/<br />
Download.aspx<br />
306 The Access to Medicines Index 2014,<br />
Haarlem, The Netherlands: Access to<br />
Medicine Foundation, November<br />
2014, available online here: http://<br />
www.accesstomedicineindex.org/<br />
sites/2015.atmindex.org/files/2014_<br />
accesstomedicineindex_fullreport_<br />
clickablepdf.pdf; Ellen ’t Hoen,<br />
“Access to Cancer Treatment: A study<br />
of medicine pricing issues with<br />
recommendations for improving<br />
access to cancer medication,” Report<br />
prepared for Oxfam, 2 May 2014,<br />
available online here: https://www.<br />
oxfam.org/sites/www.oxfam.org/files/<br />
file_attachments/rr-access-cancer-<br />
NOTES <strong>AND</strong> REFERENCES<br />
178
Change language